Key facts
- This page summarizes Laura E. Niklason's Form 4 filing for Humacyte, Inc. (HUMA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 Jun 2026, 17:57.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.